NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $43.20.

Several equities research analysts have weighed in on the company. The Goldman Sachs Group assumed coverage on NewAmsterdam Pharma in a research note on Thursday, July 17th. They set a “neutral” rating and a $27.00 price objective on the stock. HC Wainwright assumed coverage on NewAmsterdam Pharma in a research report on Monday. They set a “buy” rating and a $52.00 target price for the company. Wells Fargo & Company assumed coverage on NewAmsterdam Pharma in a research report on Monday, August 25th. They set an “overweight” rating and a $45.00 target price for the company. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 5th. Finally, Citigroup boosted their target price on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Friday.

Insider Activity at NewAmsterdam Pharma

In related news, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $24.29, for a total value of $1,214,500.00. Following the completion of the transaction, the insider owned 119,302 shares of the company’s stock, valued at $2,897,845.58. The trade was a 29.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James N. Topper acquired 1,260 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, September 8th. The stock was acquired at an average cost of $24.99 per share, with a total value of $31,487.40. Following the purchase, the director directly owned 3,027,864 shares of the company’s stock, valued at $75,666,321.36. This represents a 0.04% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 2,391 shares of company stock worth $58,424 and sold 226,342 shares worth $5,748,019. 20.84% of the stock is owned by company insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Large investors have recently bought and sold shares of the business. Quarry LP bought a new position in NewAmsterdam Pharma in the first quarter worth approximately $25,000. Mather Group LLC. purchased a new stake in shares of NewAmsterdam Pharma during the 3rd quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of NewAmsterdam Pharma during the 3rd quarter valued at $30,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of NewAmsterdam Pharma by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock valued at $79,000 after acquiring an additional 662 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of NewAmsterdam Pharma by 130.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company’s stock valued at $123,000 after acquiring an additional 3,390 shares during the period. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Down 3.1%

NASDAQ:NAMS opened at $36.48 on Wednesday. The business’s 50-day simple moving average is $28.32 and its two-hundred day simple moving average is $22.52. The stock has a market cap of $4.11 billion, a PE ratio of -22.52 and a beta of 0.02. NewAmsterdam Pharma has a 52 week low of $14.06 and a 52 week high of $41.47.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The firm had revenue of $19.15 million for the quarter, compared to analysts’ expectations of $1.44 million. Sell-side analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.